NCT06412510 Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
| NCT ID | NCT06412510 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Case Comprehensive Cancer Center |
| Condition | Ovarian Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 22 participants |
| Start Date | 2025-09-05 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 22 participants in total. It began in 2025-09-05 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to see whether participants who are assigned to a multimodal prehabilitation intervention during chemotherapy are able to adhere with exercise and nutrition program to prepare for their cancer surgery.
Eligibility Criteria
Inclusion Criteria: * Age 65 and older * Patients with diagnosis of advanced (Stage III or IV) epithelial ovarian, fallopian tube, or * Patients with diagnosis of pancreatic adenocarcinoma (PDAC) (Stage I, II, or III) undergoing neoadjuvant chemotherapy. * Patients with locally advanced esophageal cancer undergoing neoadjuvant chemotherapy. * Patients with locally advanced muscle invasive bladder cancer undergoing neoadjuvant chemotherapy. Exclusion Criteria: * Life expectancy less than 3 months in the opinion of the treating physician * Patients unable to provide informed consent. * Wheelchair bound patients/ physical immobility. * Severe cardiopulmonary disease defined as NYHA class III or IV * Patients with malignant bowel obstruction who will require surgical intervention or nutritional support in the form of enteral or parenteral nutrition will also be excluded. * Patients with any other comorbidity or condition, which, in the opinion of the enrolling investigator, would place the patient at unnecessarily higher greater risk or burden, or participating in the study would not be in the best interests of the patient.
Contact & Investigator
Mariam AlHilli, MD
PRINCIPAL INVESTIGATOR
Cleveland Clinic Foundation, Case Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT06412510 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06412510 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06412510 currently recruiting?
Yes, NCT06412510 is actively recruiting participants. Contact the research team at alhillm@ccf.org for enrollment information.
Where is the NCT06412510 trial being conducted?
This trial is being conducted at Cleveland, United States.
Who is sponsoring the NCT06412510 clinical trial?
NCT06412510 is sponsored by Case Comprehensive Cancer Center. The principal investigator is Mariam AlHilli, MD at Cleveland Clinic Foundation, Case Comprehensive Cancer Center. The trial plans to enroll 22 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.